Azenta's first quarter results exceeded expectations, with revenue at $154 million. The company has made progress on cost reduction initiatives, leading to the third consecutive quarter of positive free cash flow. While the market environment remains soft, Azenta is positive about its position and expects to continue outgrowing the market throughout fiscal 2024.
Revenue was $154 million, a 13% decrease year-over-year.
Organic revenue declined 15% year-over-year, excluding a 1% foreign exchange tailwind and a 1% contribution from acquisitions.
Sample Management Solutions revenue was $79 million, up 5% year-over-year.
Multiomics revenue was $63 million, up 3% year-over-year.
The company is reiterating revenue and earnings guidance for fiscal year 2024.
Visualization of income flow from segment revenue to net income